Targeting Bladder Cancer

Targeted delivery harbors the advantage of accumulating therapeutic drug in a specific organ or tissue selectively and quantitatively, independently of the site and methods of its administration. The goal of targeted delivery is to improve efficacy at a target site while simultaneously minimizing toxicity by reducing off-target accumulation. At present, Creative Biolabs provides targeted delivery services for cancer treatment and diagnostics with a variety of advanced methods. With more than ten years of experience in bio-conjugation chemistry, Creative Biolabs can provide customers with comprehensive module delivery systems targeting bladder cancer (BC).

Bladder Cancer

BC belongs to several types of cancer developing from the tissues of the urinary bladder, it caused by the uncontrolled growth of cells that line the bladder wall and have the potential to spread to other parts of the body. Some major risk factors include increasing age, smoking, and exposure to urothelial carcinogens. Transitional cell carcinomas account for >90% of tumors, others are squamous cell carcinoma and adenocarcinoma. Typical symptoms of BC include hematuria, frequency, urgency, and dysuria. 75% to 80% of BCs show as non-muscle-invasive disease, which can be managed with intravesical therapy. Currently, a novel drug-delivery system (DDS) was reported to improve the stay of the drug in the bladder and potentially enhance efficacy and therefore survival rate of the disease.

Fig.1 Levels of the bladder and bladder permeability barrier (BPB).¹

Delivery System Targeting BC

Nowadays, mycobacterium bovis bacillus Calmette-Guerin (BCG) represents the most important immunotherapy for treating BC patients. However, the incidence of recurrence and progression to invasive cancer is normally observed. Under this condition, nanotechnology serves as the targeted delivery system is an attractive and promising tool for the BC treatment. It can control drug release for extended time frames, with the ability to encapsulate multiple drugs simultaneously, reducing systemic side effects, increasing bioavailability, and increasing the viability of various routes of administration. Moreover, BC often presents high mutation rates and overexpression of tumor antigens on the tumor cell surface. Therapeutic targeting of these biomolecules may be promoted by nanotechnology strategies.

Fig.2 Non-specific and specific targeted therapeutic nanocarriers for treatment of BC.²

Targeted nanotechnology delivery systems have been used in BC clinical trials. Here are some examples:

• Albumin-bound-Paclitaxel nanoparticles (NPs) showed minimal toxicity and systemic absorption when used to treat non-muscle-invasive bladder cancers (NMIBC) during the first human intravesical phase I trial. Besides, phase II trials have confirmed minimal toxicity of intravesical nab-paclitaxel in NMIBC patients with a response rate of 35.7%. The formulation of albumin-bound-paclitaxel NPs has also been used to treat unresectable metastatic urethral cancer. After therapy, a 70% reduction in the size of the tumor was observed in addition to 19 months of progression free survival.

• Platinum agents can be loaded onto a variety of polymeric, lipid, and inorganic nanocarriers, including liposomes, NPs, and nanotubes to increase their antitumoral effects.

• In addition, cisplatin NPs was assessed in a preclinical study against NMIBC and cisplatin-loaded biocompatible poly (L-aspartic acid sodium salt) (PAA) NPs demonstrated the potential for enhanced intravesical treatment of NMIBC while reducing the local and systemic side effect.

Features of Our Services

• Prolonged drug release
• Target-specific recognition
• Minimum side effects
• Timely and cost-effective

As novel immunotherapy, targeted delivery therapy presents high potential in the treatment of cancer and various other diseases. The scientist teams from Creative Biolabs is here to serve the diverse needs of our clients and we can tailor specific service packages to fit your timeline and R&D budget. Please contact us for more information and a detailed quote.

References

1. Lu, Yilei, et al. "Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy." Frontiers in oncology 12 (2022): 879828.
2. Tang, Chao, et al. "Functional nanomedicines for targeted therapy of bladder cancer." Frontiers in Pharmacology 12 (2021): 778973.

Our services are For Research Use Only. We do not provide services to individuals.